Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial

Inclusion Criteria Age: ≥ 18 years old. Diagnosis: Histologically or cytologically confirmed IA stage non-small cell lung cancer (NSCLC) that is inoperable. ECOG Performance Status: 0-2 (Eastern Cooperative Oncology Group performance status). Previous Treatment: Patients must have received no prior systemic treatment for lung cancer. Informed Consent: Ability to provide written informed consent and willingness to comply with study requirements. Adequate Organ Function: Patients must have adequate hepatic, renal, and hematologic function as evidenced by: Bilirubin ≤ 1.5 × upper limit of normal (ULN) ALT/AST ≤ 2.5 × ULN Creatinine clearance ≥ 30 mL/min Absolute neutrophil count (ANC) ≥ 1,500 cells/μL Exclusion Criteria Other Malignancies: Active or history of other malignancies within the past 5 years, except for non-melanoma skin cancer or in situ carcinoma. Severe Concurrent Diseases: Any serious or uncontrolled medical condition such as: Cardiovascular disease (e.g., recent myocardial infarction, unstable angina, or severe arrhythmia) Uncontrolled diabetes or hypertension Active infections requiring systemic antibiotics or antivirals Pregnancy or Breastfeeding: Women who are pregnant, breastfeeding, or planning to become pregnant during the study. Immunosuppressive Therapy: Patients who have received immunosuppressive therapy within 30 days prior to enrollment. Other Contraindications: Known hypersensitivity to any of the components of the treat…